Valuation: Alvotech

Market Cap 1.83B 1.63B 1.51B 1.37B 2.57B 173B 2.61B 18.09B 7.11B 90.59B 6.85B 6.71B 289B P/E 2026 *
122x
P/E 2027 * 17.1x
Enterprise Value 2.9B 2.58B 2.39B 2.17B 4.08B 275B 4.15B 28.73B 11.29B 144B 10.89B 10.66B 459B EV / Sales 2026 *
4.45x
EV / Sales 2027 * 3.67x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+4.17%
1 week-6.51%
Current month-13.28%
1 month-14.31%
3 months+47.51%
6 months+38.95%
Current year-1.95%
1 week 4.95
Extreme 4.95
5.45
1 month 4.95
Extreme 4.95
6.53
Current year 2.94
Extreme 2.94
6.53
1 year 2.94
Extreme 2.94
8.5
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2026
Director of Finance/CFO 48 09/07/2025
Chief Tech/Sci/R&D Officer - 31/12/2022
Director TitleAgeSince
Chairman 57 31/12/2018
Director/Board Member 64 31/12/2018
Director/Board Member 58 31/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/04/26 Free

Chief Executive Officer

117,271 0.0355%
01/04/26 Sell

Founder

318,000 0.0963%
01/04/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+4.08%-6.51%-41.44%-42.05% 1.83B
+0.79%-6.16%+49.32%+74.50% 66.34B
-0.58%+6.22%+11.35%+89.80% 52.92B
+0.69%+5.33%+7.97%+74.32% 54.82B
+1.32%+2.66%+23.01%+46.42% 44.09B
+0.41%+9.50%+21.89%+128.10% 43.72B
+1.88%+3.26%+273.57%+988.64% 42.13B
-0.40%+9.85%+17.04%+59.17% 33.96B
-1.30%-0.68%+37.15%+7.04% 26.17B
+1.06%+5.72%+36.76%+26.53% 23.37B
Average +0.80%+3.82%+43.66%+145.25% 38.93B
Weighted average by Cap. +0.51%+4.80%+51.73%+169.01%

Financials

2026 *2027 *
Net sales 653M 581M 538M 488M 917M 61.83B 932M 6.46B 2.54B 32.36B 2.45B 2.4B 103B 786M 700M 648M 587M 1.1B 74.45B 1.12B 7.78B 3.06B 38.96B 2.95B 2.89B 124B
Net income 2.25M 2M 1.85M 1.68M 3.16M 213M 3.21M 22.23M 8.73M 111M 8.43M 8.25M 355M 80.1M 71.29M 66.08M 59.88M 113M 7.59B 114M 793M 311M 3.97B 300M 294M 12.67B
Net Debt 1.08B 957M 887M 804M 1.51B 102B 1.54B 10.65B 4.18B 53.32B 4.03B 3.95B 170B 1.06B 940M 871M 789M 1.48B 100B 1.51B 10.45B 4.11B 52.35B 3.96B 3.88B 167B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
18/10/26 US$5.030 +0.60% 907,729
20/10/26 US$5.120 +1.79% 1,302,515
19/10/26 US$5.030 +0.60% 907,729
16/10/26 US$5.000 -5.84% 1,059,087
15/10/26 US$5.310 +2.71% 1,156,272
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.120USD
Average target price
7.200USD
Spread / Average Target
+40.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech
  1. Stock Market
  2. Stocks
  3. ALVO Stock